MEPSGEN
PrivateLast Round
Series C
Nov 19, 2024
Total Funding Raised
$29.26M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
MEPSGEN operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Series C round in November 2024.
MEPSGEN is a biotechnology company that develops human microphysiological systems (organ-on-a-chip) and nanoparticle synthesis platforms to aid in drug discovery and development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MEPSGEN Comparables
Compare MEPSGEN with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MIMETAS | 86% | |
| InSphero | 85% | |
| NETRI | 85% |
For institutional investors. Book with your work email.
MEPSGEN Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 19, 2024 | ||||
| Series B | Jul 1, 2022 | ||||
| Series A Extension | Aug 1, 2021 | ||||
| Series A | Aug 1, 2020 | ||||
| Angel | Oct 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
MEPSGEN Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KIWOOM Securities Co., Ltd. | Series B |
| SBI Investment Korea | Series C, Series A Extension |
| KB Securities | Series C |
| Kolon Investment | Series B |
| Kolon Investment | Series B |
| Yuanta Investment | Series C |
| Korea Development Bank | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 75% MoM.
- Jun 29, 2026
Open roles increased to 22, 6x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesOct 28, 2026
MEPSGEN Co. announces the launch of NanoCalibur(R) Mini, an automated system for small-volume nanoparticle formulation designed for early-stage drug discovery and development, in South Korea.
For institutional investors. Book with your work email.
MEPSGEN Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MEPSGEN's valuation, stock price, and market status.
Is MEPSGEN a public or private company?
MEPSGEN is a private company.
What is the current stock price of MEPSGEN?
MEPSGEN is a private company, so its shares have no public market price. Caplight tracks MEPSGEN's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MEPSGEN worth (valuation)?
Valuation information for MEPSGEN is not publicly available.
Can I buy MEPSGEN stock?
MEPSGEN shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MEPSGEN's last funding round?
MEPSGEN's most recent funding round was Series C on November 19, 2024.
Who are the main investors in MEPSGEN?
Key investors in MEPSGEN include Yuanta Investment.
Will MEPSGEN IPO soon?
No public IPO plans have been announced for MEPSGEN.
How can I track MEPSGEN secondary market activity?
Caplight tracks bids, offers, and trades in MEPSGEN's shares on secondary markets.